MAY 26, 2016 12:43 PM PDT

Suppressing Peant Allergy Anaphylaxis with Histamine Blockers

WRITTEN BY: Kara Marker
All antihistamine drugs on the market today block only the H1 receptor, but there are three more histamine receptors that are involved in the allergic immune response that are present on the surface of several body cell types. New research shows that simultaneously blocking two different histamine receptors can inhibit gastrointestinal symptoms to the point where people with peanut allergies might be able to safely consume peanut products.
 

Recent studies have shown that exposure early in life to peanuts can help prevent the development of peanut allergies as people mature. However, for people who already have an allergy, the only existing, effective measure to prevent life-threatening symptoms is to avoid contact with the allergen. A new study from National Jewish Health might be the answer for people with both peanut allergies and peanut cravings.

The study, which was recently published in the journal Allergy, involved mice models of peanut allergy that were already sensitized to peanuts. The researchers first treated the mice with oral doses of H1 receptor blockers and H4 receptor blockers separately, done during the “challenge phase” as the mice encountered peanuts. 

The response was essentially the same for mice receiving either individual dose of either H1 or H4 receptor blockers: “partial suppression, plus decreased numbers of dendritic cells in mesenteric lymph nodes and lamina propria.”

On the other hand, when researchers gave oral doses of a combination of H1 and H4 receptor blockers during the challenge phase, gastrointestinal symptoms like diarrhea, intestinal inflammation, and others were prevented almost entirely. 

Histamine is a chemical released by immune cells like basophils and mast cells in times of allegy as well as in times of stress. Histamine can trigger a variety of responses associated with an allergy, such as inflammation, itchiness, and mucus production. These responses occur because of  histamine’s effect on the body: dilating blood vessels, bronchoconstriction. In addition to playing a primary role in food allergies, histamine is also a key player in conditions like asthma and hay fever. 

Throughout the study, researchers measured a variety of interactions to understand the full story of how blocking histamine receptors inhibits the allergic response: dendritic cell chemotaxis, calcium mobilization, and antigen-presenting cell function. The H1 receptor antagonist they used, loratadine, is a drug present in common allergy alleviator Claritin. The H4 receptor antagonist is an experimental drug, called JNJ7777120. 

The also completed several in vitro experiments to visualize at the cellular level how the antihistamine drugs suppressed the allergic response. They saw the histamine receptor blockers work by inhibiting accumulation and function of dendritic cells, antigen-presenting cells of the immune system that normally present peanut proteins to T lymphocytes in people with peanut allergies.
As many as 15 million Americans are believed to have some sort of food allergies, and many are at risk for life-threatened anaphylaxis. This exciting new research shows much promise for treating the most severe allergies and improving the quality of life for millions of people with allergies.
 

Sources: National Jewish Health, Allergy & Immunology Associates of Michigan, Food Allergy & Research Education
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
OCT 12, 2020
Microbiology
Researchers May Have Found a Way to Cure Rotavirus Infections
OCT 12, 2020
Researchers May Have Found a Way to Cure Rotavirus Infections
Rotaviruses are very contagious. They are the most common cause of diarrhea in children and are estimated to cause about ...
OCT 17, 2020
Clinical & Molecular DX
Imaging Innovation Set to Ease the Pain of Osteoarthritis
OCT 17, 2020
Imaging Innovation Set to Ease the Pain of Osteoarthritis
In osteoarthritis, the joint cartilage that cushions bones begins to break down, causing debilitating pain and stiffness ...
OCT 14, 2020
Chemistry & Physics
The CRISPR Nobel Win from Different Angles
OCT 14, 2020
The CRISPR Nobel Win from Different Angles
CRISPR-Cas9 was THE buzz word in the world of science after the Nobel Chemistry Prize announcement last week. But depend ...
OCT 18, 2020
Earth & The Environment
Pandemic-enforced lockdowns cut premature deaths from air pollution
OCT 18, 2020
Pandemic-enforced lockdowns cut premature deaths from air pollution
A new study published in The Lancet Planetary Health reports that pandemic-enforced lockdowns in China and Europe h ...
Loading Comments...